The proportion of cancer patients mounting detectable CEA-specific IFN-γ T cell responses diminished in comparison to healthy age-matched controls (Fig. 1a) and further declined as the tumour became more advanced (Fig. 1b). This evidence concerns the gene IFNG and cancer.